A detailed history of Braidwell LP transactions in Argenx Se stock. As of the latest transaction made, Braidwell LP holds 166,924 shares of ARGX stock, worth $92.4 Million. This represents 2.25% of its overall portfolio holdings.

Number of Shares
166,924
Previous 219,824 24.06%
Holding current value
$92.4 Million
Previous $86.5 Billion 17.06%
% of portfolio
2.25%
Previous 2.79%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$356.01 - $451.55 $18.8 Million - $23.9 Million
-52,900 Reduced 24.06%
166,924 $71.8 Billion
Q1 2024

May 15, 2024

BUY
$356.95 - $413.29 $23.8 Million - $27.5 Million
66,620 Added 43.48%
219,824 $86.5 Billion
Q4 2023

Feb 14, 2024

BUY
$338.91 - $506.01 $51.9 Million - $77.5 Million
153,204 New
153,204 $58.3 Billion
Q1 2023

May 15, 2023

SELL
$334.23 - $403.65 $8.22 Million - $9.93 Million
-24,600 Reduced 50.0%
24,600 $9.17 Billion
Q4 2022

Feb 14, 2023

BUY
$342.17 - $402.31 $16.8 Million - $19.8 Million
49,200 New
49,200 $18.6 Billion

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $30.6B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Braidwell LP Portfolio

Follow Braidwell LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

News

Stay updated on Braidwell LP with notifications on news.